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Summary
 
Cervical cancer is the second most prevalent cancer in women worldwide. It is linked to 
infection with human papillomavirus (HPV). As the virus cannot be propagated in culture, 
vaccines based on virus-like particles have been developed and recently marketed. However, 
their high costs constitute an important drawback for widespread use in developing 
countries, where the incidence of cervical cancer is highest. In a search for alternative 
production systems, the major structural protein of the HPV-16 capsid, L1, was expressed 
in tobacco chloroplasts. A very high yield of production was achieved in mature plants 
(~3 mg L1/g fresh weight; equivalent to 24% of total soluble protein). This is the highest 
expression level of HPV L1 protein reported in plants. A single mature plant synthesized 
~240 mg of L1. The chloroplast-derived L1 protein displayed conformation-specific epitopes 
and assembled into virus-like particles, visible by transmission electron microscopy. 
Furthermore, leaf protein extracts from L1 transgenic plants were highly immunogenic in 
mice after intraperitoneal injection, and neutralizing antibodies were detected. Taken 
together, these results predict a promising future for the development of a plant-based 
 
vaccine against HPV.
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Introduction
 
Cervical cancer is the second most prevalent cancer in women
worldwide and the most common cancer in developing
countries. Every year, approximately 500 000 women
develop cervical cancer, 80% of whom live in poor countries
where screening programmes are inadequate or absent
(Franceschi, 2005). Every year, this disease causes about
200 000 deaths. In 1995, the World Health Organization
declared some types of human papillomavirus (HPV) to be
carcinogenic in humans and to be responsible for cervical
cancer (IARC, 1995). Nearly 120 HPV strains have been
identified so far, and two-thirds of cervical cancer cases are
associated with infection by either HPV-16 (51%) or HPV-18
(16%). Taken together, these data led the scientific commu-
nity to increase their interest in developing an HPV vaccine.
This virus cannot be propagated in culture, hindering the
generation of attenuated or dead HPV particles for vaccine
purposes.
The major structural protein of the HPV capsid, L1, is the
most highly conserved of all papillomavirus proteins. When
expressed in a variety of heterologous systems, L1 protein
self-assembles into non-infectious virus-like particles (VLPs)
that closely resemble the native spherical virion of ~50–55 nm
in diameter. A single VLP is composed of 72 pentameric
capsomers. Each capsomer contains five monomers of
the 55-kDa L1 protein (Sapp 
 
et al
 
., 1998). Papillomavirus
VLPs have been reported previously to efficiently induce both
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humoral and cellular responses. In addition, it has been
demonstrated that immunization with HPV VLPs provides
protection against challenge with the infectious virus in animal
models (Breitburd 
 
et al
 
., 1995; Suzich 
 
et al
 
., 1995). Therefore,
VLPs are the prime candidates for the development of
prophylactic vaccines against HPV.
Recently, two subunit vaccines against HPV have been
marketed as prophylactic cervical cancer vaccines. In both
cases, the selected antigen is the L1 protein. One of them,
the tetravalent vaccine, covers HPV types 16, 18, 6 and 11
and the expression system is yeast. The other, a bivalent
vaccine, includes L1 from HPV-16 and HPV-18 produced in
insect cells. However, despite the high probability for these
two vaccines to promote immunity against high-risk HPV
infection, their high cost prohibits their widespread use in
developing countries (Sanders and Taira, 2003; Crum 
 
et al
 
.,
2006; Kane 
 
et al
 
., 2006; Schiller and Nardelli-Haefliger, 2006),
where the highest cervical cancer mortality rates have been
reported, especially in sub-Saharan Africa (Pisani 
 
et al
 
., 1999).
Therefore, a primary challenge is to develop cost-effective
HPV vaccines, available for the developing world.
Transgenic plants are potentially one of the most economical
systems for the production of recombinant vaccine proteins.
Studies in this field have indicated that transgenic plants
can produce recombinant proteins 10–100 times cheaper
than cell culture systems (Kusnadi 
 
et al
 
., 1997; Mison and
Curling, 2000). Cost reductions would be even higher if plant
material could be used directly as an oral vaccine (e.g.
capsules of dried powder), thus avoiding purification steps.
It has also been demonstrated that plant-derived antigens
can induce immune responses against important human or
animal pathogens (Streatfield and Howard, 2003; Floss 
 
et al
 
.,
2007). However, one of the main drawbacks of antigen
production in plants is the low level of recombinant protein
expression when the transgene is integrated into the nuclear
genome. Average antigen expression levels are in the range
of 0.01%–0.4% of total soluble protein (TSP) (Daniell 
 
et al
 
.,
2001b).
HPV-16 L1 has been expressed constitutively in tobacco
and potato by nuclear transformation (Biemelt 
 
et al
 
., 2003;
Varsani 
 
et al
 
., 2003; Liu 
 
et al
 
., 2005) and transiently in
 
Nicotiana benthamiana
 
 using a viral vector (Varsani 
 
et al
 
.,
2006). HPV-11 L1 has also been reported to be produced in
potato (Warzecha 
 
et al
 
., 2003). All of these publications
reported very low levels of antigen expression (< 1% of TSP).
In contrast, transgenic tobacco plants expressing a human
codon-optimized 
 
L1
 
 gene linked to a chloroplast-targeting
signal expressed L1 protein at levels up to 11% of TSP
(Maclean 
 
et al
 
., 2007). Furthermore, by agroinfiltration of the
same genetic construct, L1 protein expression increased to
up to 17% of TSP (Maclean 
 
et al
 
., 2007). Concentrated protein
extracts containing this antigen were reported to be
immunogenic in mice, and elicited neutralizing antibodies.
Agroinfiltration, however, is a complex method to scale up, and
is therefore not the most useful choice for mass production.
An alternative expression system to nuclear transformation
is plastid genetic engineering. Transformation of chloroplasts
allows for very high levels of foreign protein because of the
high copy number of the transgene per cell (for a review, see
Daniell 
 
et al
 
., 2002; Bock and Khan, 2004; Maliga, 2004).
Additional advantages of this recombinant protein expres-
sion system include transgene containment via maternal
inheritance of plastids, lack of gene silencing, multigene
expression in a single transformation step and expression of
foreign proteins lacking methionine as the N-terminal amino
acid (Fernández-San Millán 
 
et al
 
., 2007). This system has
been demonstrated to be effective for the expression of
vaccine antigens against several human and animal diseases
(Daniell, 2006). Average expression levels are in the range of
4%–20% of TSP, with maximum values of 31% in the case
of canine parvovirus antigen expression (Molina 
 
et al
 
., 2004).
Mice and rabbits injected with chloroplast-derived vaccines
developed specific immune responses and neutralizing
antibodies against the pathogens (Molina 
 
et al
 
., 2005;
Chebolu and Daniell, 2007). In the case of anthrax and
tetanus, mice immunized with tobacco-derived vaccines were
protected against lethal toxin challenge (Koya 
 
et al
 
., 2005;
Tregoning 
 
et al
 
., 2005). Together, these data indicate that
chloroplast-transformed plants can be an effective source of
purified antigens for prophylactic vaccines.
In this study, the expression of the HPV-16 L1 antigen in
tobacco chloroplasts was analysed. The ability of this molecule
to self-assemble into VLPs when expressed in the chloroplast
was also investigated. Finally, the immunogenicity of plant-
derived L1 was verified after intraperitoneal administration
in mice.
 
Results
 
Vector construction
 
The pAF vector was engineered for tobacco plastid transfor-
mation. This vector (5913 bp in length) includes the following
sequences (Figure 1a): the 
 
trnI
 
 and 
 
trnA
 
 border sequences,
homologous to the inverted repeat regions of the tobacco
plastid genome; the aminoglycoside 3
 
′
 
-adenylyltransferase
gene (
 
aadA
 
) from 
 
Escherichia coli
 
, conferring resistance to both
spectinomycin and streptomycin, driven by the constitutive
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promoter of the rRNA operon (
 
Prrn
 
), and the consensus
GGAGG ribosome binding site; a multiple cloning site between
the end of the 
 
aadA
 
 coding sequence and the 
 
psbA
 
 termina-
tor with the following unique sites: 
 
Eco
 
RV, 
 
Kpn
 
I, 
 
Sal
 
I, 
 
Hin
 
cII,
 
Not
 
I, 
 
Xba
 
I and 
 
Spe
 
I.
The 
 
L1
 
 gene of HPV-16 was polymerase chain reaction
(PCR) amplified, fused to the promoter and 5
 
′
 
-untranslated
region (5
 
′
 
-UTR) of the 
 
psbA
 
 gene and finally introduced into
the multiple cloning site of pAF, rendering the final vector
pAF-L1 (Figure 1b). The 
 
L1
 
 gene encodes an aspartate residue
at amino acid position 202 instead of the histidine residue of
the prototype. This change allows the efficient assembly of
HPV-16 L1 molecules (Kirnbauer 
 
et al
 
., 1993). The regulatory
sequences of the 
 
psbA
 
 gene were chosen because of the
high levels of heterologous gene expression they confer in
transplastomic plants (Fernández-San Millán 
 
et al
 
., 2003;
Molina 
 
et al
 
., 2004).
 
Determination of chloroplast integration and 
homoplasmy
 
Shoots developed after the second round of selection on
spectinomycin were analysed for transgene integration by
PCR. Primer 3P binds on the chloroplast genome upstream of
the 
 
trnI
 
 gene outside the vector integration site, and primer
3M binds to the 
 
aadA
 
 gene (Figure 1b). The resulting PCR
product is specific for transformed genomes and cannot be
obtained from wild-type or nuclear transgenic plants. An
analysis of 22 independent shoots showed that all were PCR
positive (data not shown). Southern blot analysis was
performed to verify site-specific integration and to confirm
homoplasmy. Total plant DNA was digested with 
 
Hin
 
dIII. The
flanking region probe (P1, Figure 1c) identified a 7.8-kb
fragment in the wild-type plant, and a 10.7-kb fragment in
the chloroplast transgenic plants (Figure 1d). The absence of
7.8-kb bands in the transformed lines indicated homoplasmy.
To confirm that the 10.7-kb fragment contained the 
 
L1
 
sequence, the same membrane was re-probed with the P2
probe (Figure 1c). Hybridization was observed in the eight
transgenic lines, but was absent in the wild-type control plant
(Figure 1e). Southern blot analysis of the T
 
1
 
 generation of three
transgenic lines confirmed that homoplasmy was maintained
(data not shown).
 
Expression and quantification of the L1 protein
 
The recombinant protein in transformed chloroplasts was
detected by western blot with the Cam Vir-1 monoclonal
antibody (mAb), which is specific for HPV-16 L1 protein. A
55-kDa band of the expected size for the L1 protein was
detected in the three independent transgenic lines analysed
(Figure 2a). This band showed an electrophoretic mobility
similar to that of the L1 protein purified from insect cells,
which was used as a control. Higher molecular weight signals
indicated the presence of multimeric structures, despite the
denaturing conditions during sample preparation and
electrophoresis. The foreign protein was present in both the
soluble and insoluble fractions, suggesting the presence of
insoluble aggregates or the association of L1 protein with the
thylakoid membranes of grana. No signal was present in
protein samples extracted from the wild-type tobacco control
plant. All of the three transgenic lines analysed showed
Figure 1 Schematic representation of plastid genome transformation 
with the human papillomavirus L1 gene (constructs not drawn to scale). 
(a) Main components of the pAF vector for transformation of tobacco 
chloroplasts. (b) Map of the wild-type and L1-transformed genomes. 
Regions for homologous recombination are underlined in the native 
chloroplast genome. The L1 sequence is driven by the psbA promoter. 
The annealing sites of the primers (3P and 3M) used to test the integration 
of the cassette into the chloroplast genome are shown. (c) The 0.8-kb 
fragment (P1) of the targeting region for homologous recombination and 
the 0.45-kb L1 sequence (P2) were used as probes for Southern blot 
analysis. (d, e) Southern blot analysis of eight independent transgenic 
lines. The blots were probed with P1 (d) and P2 (e). aadA, aminoglycoside 
3′-adenylyltransferase; MCS, multicloning site; Prrn, 16S rRNA promoter; 
3′psbA, terminator region of the psbA gene; trnI, trnA, original sequences 
of the chloroplast genome; WT, wild-type.
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similar expression levels relative to leaf fresh weight (FW).
The effect of leaf age on L1 protein expression was analysed
in plants grown in the glasshouse for 60 days. Monomers
of 55 kDa and higher molecular weight structures were
observed in young and mature leaves (Figure 2b). Two bands
of approximately 39 and 20 kDa, probably L1 degradation
products, were clearly detected in the soluble fraction of old
leaves (Figure 2b). Accordingly, aggregates of high molecular
weight were not observed. This pattern was more pronounced
in the insoluble fraction, with multiple bands of degradation.
The amount of L1 protein was quantified by enzyme-linked
immunosorbent assay (ELISA) using Cam Vir-1 or H16.V5
mAbs. Cam Vir-1 recognizes linear and conformational L1
epitopes, whereas H16.V5 recognizes a conformational epitope
only present in non-denatured HPV-16 VLPs (Christensen
 
et al
 
., 1996). Both antibodies recognized the chloroplast-
derived L1 protein in an equivalent manner. This shows that
chloroplast-derived L1 protein displays mostly conformation-
specific epitopes. The three independent transgenic lines
expressed the recombinant protein at high levels (Figure 2c),
ranging from 2.1 to 3.7 mg L1/g FW. This is equivalent to
20%–26% of TSP. The high levels of L1 protein were
confirmed when total protein extracts from chloroplast
transgenic plants were separated by sodium dodecylsulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and stained
with Coomassie brilliant blue. A 55-kDa band corresponding
to the L1 expected molecular size was observed in transgenic
lines, but was absent in the wild-type plant (Figure 2d). The
relatively low intensity of the detected band was probably a
result of the presence of multimeric structures of higher
molecular weight, only detected by western blot (Figure 2a).
In order to quantify the yield of L1 protein per plant and the
relative contributions of different leaves, recombinant protein
levels were calculated by taking into account the average
number and weight of leaves. Old (bleached and senescing)
leaves were discarded from this calculation because of the
high L1 protein degradation process observed by western
blotting (Figure 2b). A total of 242.2 mg of L1 antigen was
produced by a single plant (Table 1).
 
Figure 2
 
(a, b) Immunoblot analysis of L1 protein expression in 
transgenic tobacco chloroplasts. Soluble and insoluble proteins extracted 
from 1.5 mg leaf fresh weight/well were loaded. (a) Three independent 
transgenic lines and a wild-type (WT) plant used as a negative control 
were analysed. (b) Young (Y), mature (M) and old (O) leaves from line 1 
and WT plants were analysed. Blots were detected using Cam Vir-1 anti-
L1 as primary antibody. Purified 6 
 
×
 
 His-L1 expressed in insect cells (L1) 
was used as a positive control (150 ng). (c) Recombinant protein 
quantification in transgenic tobacco chloroplasts. L1 accumulation in 
three independent transgenic lines and wild-type plants was analysed by 
enzyme-linked immunosorbent assay (ELISA), using Cam Vir-1 (striped) 
or H16.V5 (white) as primary antibody. The data are presented as the 
means and standard errors (
 
n 
 
= 8, four plants/line) of samples from 
young and mature leaves. (d) Coomassie blue-stained sodium 
dodecylsulphate-polyacrylamide gel electrophoresis of plant samples 
equivalent to those shown in (b). Total protein extracted from 6 mg leaf 
fresh weight/well was loaded. L1, 3 
 
µ
 
g of insect cell-derived and purified 
L1 protein; M, molecular weight marker; WT, wild-type; RbcL, Ribulose 
bisphosphate carboxylase large subunit.
 Assembly of VLPs in tobacco chloroplasts
 
431
 
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd, 
 
Plant Biotechnology Journal
 
, 
 
6
 
, 427–441
 
L1 protein synthesized in the chloroplast self-assembles 
into VLPs
 
Data from western blots and ELISA with the conformational
H16.V5 mAb (Figure 2) demonstrated the successful expres-
sion of L1, and suggested that the recombinant protein was
present as higher order molecular structures in tobacco chloro-
plasts. The sensitivity of viral proteins to protease digestion
is an informative method to assess their native conformation.
Purified L1 capsomers (viral pentamers of L1) and VLPs treated
with trypsin yielded a 42-kDa product resulting from cleavage
at R412 (87 amino acid residues from the carboxy terminus)
(Li 
 
et al
 
., 1997). Insect cell- and chloroplast-derived L1
proteins treated with trypsin were reduced to the expected
42-kDa species (Figure 3a). By contrast, the monomeric and
denatured L1 protein produced in insect cells was totally
digested with trypsin. This result confirms that capsomers are
correctly assembled.
To determine whether L1 assembles into VLPs, plant extracts
were sedimented through a sucrose cushion, followed by a
CsCl equilibrium density gradient. L1 protein was detected by
ELISA in the different fractions using the conformational
H16.V5 mAb. Most of the L1 protein concentrated in
fractions 1–4 at a density of 1.27–1.32 g/mL (Figure 3b). A
western blot also detected the 55-kDa L1 protein in fractions
1–4, as expected (Figure 3c). Fraction 3 (density of 1.28 g/mL)
of the CsCl gradient was analysed by electron microscopy
to determine whether VLPs were actually assembled within
Table 1 Yield per plant of the human papillomavirus L1 protein expressed in tobacco chloroplasts (n = 4 plants)
Leaf age
Average number 
of leaves per plant
Fresh weight (FW) 
per leaf (g)
Average amount 
of L1 (mg/g FW)
Average amount 
of L1 (total mg)
Young 3.1 5.8 2.5 45.1
Mature 6.6 9.9 3.0 197.1
Total recombinant protein (mg) per plant 242.2
Young: small, dark-green leaves from the upper part of the plant; mature: large, well-developed leaves from the middle part of the plant.
 
Figure 3
 
Purification of virus-like particles (VLPs) from transgenic 
tobacco chloroplasts. (a) Trypsin digestion of purified L1 proteins. 
western blot of insect cell-derived denatured and monomeric L1 (1, 2), 
insect cell-derived VLPs (3, 4) and chloroplast-derived VLPs (5, 6). Protein 
samples were untreated (1, 3, 5) or trypsin digested (2, 4, 6). (b) Detection 
of L1 by enzyme-linked immunosorbent assay (ELISA) in fractions of a 
CsCl gradient. The conformational H16.V5 anti-L1 monoclonal antibody 
(mAb) was used as primary antibody. The broken line indicates the density 
of the different fractions. (c) Western blot of the different fractions. The 
band corresponds to the L1 monomeric form. (d) Electron microscopy of 
negatively stained chloroplast-derived VLPs from fraction 3 of the CsCl 
gradient. Bar, 100 nm. (e) Sucrose sedimentation analysis of L1 derived 
from transgenic tobacco chloroplasts, detected by ELISA with the 
conformational H16.V5 mAb. Soluble proteins from tobacco leaves and 
insect cells were fractionated by sucrose gradient centrifugation (fraction 
1 corresponds to the tube bottom). Wild-type plant was used as a 
negative control. The broken line indicates the refractive index of the 
different fractions. The arrow indicates the fraction in which the standard 
(corresponding to capsomer size) migrated.
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tobacco chloroplasts. Spherical particles of approximately
55–65 nm in diameter (Figure 3d) were observed in samples
from transgenic plants. The assembly of particles of different
sizes has been observed previously when HPV-16 L1 was
expressed in the cytoplasm of tobacco cells (Biemelt 
 
et al
 
.,
2003; Maclean 
 
et al
 
., 2007). The morphology of the chloroplast-
derived VLPs was qualitatively identical to that of VLPs
produced in insect cells by recombinant baculovirus infection
(data not shown).
To determine the proportion of L1 protein that is in an
assembled form, crude extracts of tobacco leaves and insect
cells (as a control) were subjected to sucrose sedimentation
analysis. After sucrose gradient centrifugation, insect cell-
derived VLPs were detected with the conformational H16.V5
mAb in fractions 10–14 (Figure 3e). Chloroplast-derived L1
was mainly present in fractions 12–17, displaying a maximum
peak in fraction 15 (a similar pattern was observed when sucrose
gradient fractions were detected with Cam Vir-1 mAb; data
not shown). VLPs of different sizes were detected in these
fractions by electron microscopy (data not shown). The shift
to lower sedimentation coefficients indicates that approximately
30% of chloroplast-synthesized VLPs are similar in size to true
virion particles (55 nm in diameter), whereas 70% are particles
of smaller size. The treatment of insect cell-derived VLPs with
 
β
 
-mercaptoethanol led to disassembly into capsomers with a
lower sedimentation coefficient, which were concentrated
in fractions 17 and 18 (data not shown). Catalase, used as
capsomer sedimentation marker, also migrated in fraction
17 (Figure 3e). Only a small proportion of capsomers was
present in VLPs purified either from insect cells or plant
extracts (fraction 17). This demonstrates that chloroplast-derived
L1 protein mostly self-assembles into structures higher than
capsomers.
A further analysis to confirm the assembly of VLPs was
performed. The ELISA reactivity of chloroplast-derived L1
protein and VLPs purified from insect cells was investigated
using H31.D24 and H16.V5 mAbs. H31.D24 recognizes a
conserved linear epitope present in both denatured and
non-denatured L1 proteins of high-risk HPV types, and
H16.V5 recognizes a type-specific conformational epitope.
L1 protein was not detected in extracts from the wild-type
tobacco control plant (Figure 4). A similar reactivity of insect
cell- and plant-derived VLPs was observed with both mAbs,
thus confirming again that chloroplast-derived L1 was
assembled into capsomers or VLPs. The optical density at
492 nm (OD
 
492 nm
 
) in the first dilution (20-fold) from plant
extracts was lower than that in the 40- and 80-fold dilutions.
This could be the result of the higher concentration of
inhibitory compounds at the lower dilution.
 
In situ
 
 electron microscopy and immunogold labelling
 
Palisade mesophyll cells from leaves of both transgenic and
wild-type tobacco plants presented a highly ordered disposition
and an elongated, cylinder-like morphology. In cross-sectional
views (Figure 5a), a large vacuole could be seen occupying
most of the cell volume and displacing the abundant chloro-
plasts to a peripheral location. Grana in chloroplasts looked
apparently normal in both transgenic and wild-type plants.
However, several electron-dense, rounded particles could
be observed dispersed in the stroma of transgenic plants
(Figure 5b), often in close proximity to the grana. At higher
magnification, these particles frequently appeared as ~30 nm-
diameter, electron-dense rings enclosing a lighter central
region (inset in Figure 5b). Such particles were never observed
in chloroplasts of wild-type tobacco plants (Figure 5c).
Immunogold labelling of transgenic mesophyll cells with
anti-L1 Cam Vir-1 mAb presented a high signal-to-noise ratio,
with gold particles decorating chloroplasts almost exclusively
Figure 4 Comparative analysis of insect cell-derived and 
chloroplast-derived virus-like particle (VLP) binding by enzyme-linked 
immunosorbent assay (ELISA). L1 protein was detected using H31.D24 
and H16.V5 monoclonal antibodies (mAbs). H31.D24 binds a linear 
epitope present in denatured and native VLPs, and H16.V5 binds a 
conformational epitope. Crude extracts (100 mg of leaf tissue in 50 µL of 
phosphate-buffered saline) from transgenic and wild-type plants were 
analysed. VLPs purified from insect cells were used as a control. 
, wild-type extract; , chloroplast-derived extract; , insect 
cell-produced VLPs.
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(Figure 5d). Isolated gold particles were very occasionally
observed in the cytoplasm, but never in the nucleus, vacuoles,
cell walls, starch or lipid deposits within chloroplasts or any
other cell compartments. Within chloroplasts, gold particles
were observed dispersed throughout the stroma and
occasionally formed small clusters of two or three particles
(Figure 5d). Individual gold particles were also observed at
the boundaries of grana stacks (Figure 5d), and also within
stacks, over thylakoid membranes (Figure 5e). No clusters
were observed over thylakoids. Controls performed in
parallel were almost devoid of labelling (Figure 5f).
Plant-derived HPV-16 L1 VLPs are immunogenic
In order to study the immunogenicity of plant-produced
VLPs, Balb/c mice were immunized intraperitoneally with
partially purified leaf extracts from L1-transformed plants
or wild-type plants (control). Freund’s adjuvant or aluminium
hydroxide was used as adjuvant. Anti-L1 antibodies were
detected in both groups after the first immunization (Figure 6a).
Titres of antibodies increased with both boosters. No antibodies
(titre < 10) were detected in the group immunized with
wild-type plant extracts. Both adjuvants led to a similar L1
immune response, with final antibody titres of 20 000
(Freund’s) and 42 000 (aluminium) after the second booster
(Figure 6a). When mice sera were analysed against denatured
VLPs, the titres were negligible (titre < 10). In accordance
with our results, similar titres were obtained using plant
protein extracts from tobacco plants in which L1 protein was
targeted to the chloroplast (Maclean et al., 2007).
To characterize the L1-induced immune response, mice
sera were analysed after the second booster. Denatured and
non-denatured VLPs were blotted on to nitrocellulose filters
and incubated with H16.V5 conformational mAb, Cam Vir-1
or the pooled sera of mice immunized with aluminium as an
adjuvant. None of the antibodies or sera reacted with bovine
serum albumin (BSA) used as negative control (Figure 6b).
Although Cam Vir-1 equally recognized both denatured and
non-denatured VLPs, H16.V5 reacted only with correctly
assembled VLPs. Mice sera displayed a similar behaviour to
H16.V5 mAb, identified by a strong spot signal when it
reacted with the non-denatured VLP sample and a very weak
signal with denatured VLPs (Figure 6b). This result and the
negligible titres against denatured VLPs strongly suggest that
antibodies elicited with L1 plant protein extracts are mostly
directed against L1 conformational epitopes, and, in addition,
that chloroplast-derived L1 protein is preferentially assembled
into higher order structures.
Figure 5 In situ electron microscopy and 
immunogold labelling. (a) Cross-section of 
mesophyll cells of a transgenic tobacco leaf 
showing the large central vacuole (v) and the 
peripheral belt of chloroplasts (chl). 
(b) Chloroplast of a transgenic plant showing 
the presence of round, electron-dense particles 
(arrows) in the stroma (s) or associated with 
grana stacks (g). Inset in (b) shows a 
magnification of one particle in which an outer 
dense ring can be discerned. (c) Chloroplast of a 
wild-type plant; no dense particles are present. 
(d, e) Immunogold labelling of L1 protein in 
chloroplasts of a representative L1 transgenic 
plant; sta, starch granule. (f) Control excluding 
primary antibody. Bars: (a) 2 µm; (b–f) 200 nm; 
inset in (b) 100 nm.
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In addition, the presence of neutralizing antibodies was
investigated in sera from mice immunized with plant extracts.
Neutralization was not detected in sera from mice immunized
with wild-type tobacco extracts, used as negative control.
In contrast, neutralizing antibodies were detected in sera
from mice immunized with plant extracts from L1-transformed
plants at a dilution of 1 : 100 (aluminium adjuvant) and 1 : 400
(Freund’s adjuvant). As a positive control, mice immunized
with VLPs purified from insect cells elicited a neutralizing
antibody titre of 1 : 400.
Discussion
Transgenic tobacco plants expressing the major structural
protein L1 of HPV-16 in their chloroplasts have been developed.
High expression levels of L1 foreign protein (~3 mg/g FW;
equivalent to 24% of TSP) have been achieved. This is the
highest expression level of HPV L1 protein reported in plants.
Several antigenic proteins have been expressed previously in
tobacco chloroplasts, with accumulation levels in the range
of 4%–20% of TSP (Daniell, 2006). It is assumed that the
transgene hyperexpression obtained in the chloroplast is a
result of the high gene copy number in the plastid genome
(up to 10 000 copies/cell) and of the higher stability of
proteins in this organelle compared with that of proteins in
the cytoplasm or other subcellular compartments.
HPV-16 L1 has been expressed previously in potato and
tobacco plants by nuclear transformation, either transiently
or stably, with yields lower than 0.1 mg/g FW. Recently, chloro-
plast targeting of L1 using a transit peptide fused to the L1
sequence allowed for significantly higher levels of accumula-
tion of L1 protein (up to 0.65 mg/g FW) (Maclean et al., 2007).
This increase in foreign protein accumulation, in contrast
with that achieved in the cytoplasm, could be attributed to
the different protein hydrolysing machinery to which the
recombinant protein was subjected. A second possibility
could be a higher protein stability achieved through the
correct folding of the L1 protein by the assistance of plastid-
specific chaperones. These molecular processes are thought
to be equal for any foreign protein present in the stroma of
the chloroplast, irrespective of its point of origin (a nuclear
gene whose protein is transported to the chloroplast or a
plastid gene). Therefore, the approximately fivefold higher
expression obtained by chloroplast transformation (0.65 vs.
3 mg/g FW) can only be explained by the high copy number
of the transgene in the plastid genome and the high transla-
tion rate driven by the 5′-UTR of the psbA gene.
In this study, it was estimated that a single transgenic
tobacco plant is able to synthesize ~240 mg of L1 protein.
Old leaves were excluded from this calculation because of
high proteolytic degradation of the recombinant protein. This
point is relevant if the process is to be scaled up, and must be
analysed for each recombinant protein. Despite the fact
that the L1 protein content in old leaves is relatively high, the
mixture of intact L1 molecules and multiple degradation
products may be difficult to eliminate, and could be detrimental
for the final use of the protein.
Despite the high accumulation of L1 protein in tobacco chloro-
plasts, transformed plants grew normally in the glasshouse,
with no alteration of the phenotype. Ultrastructural analysis
of mesophyll cells by transmission electron microscopy
indicated that chloroplasts were normal in shape and size.
Immunogold labelling showed a homogeneous distribution
of L1 protein within the chloroplast. The presence of L1
Figure 6 Analysis of the L1-induced antibody response in mice. (a) Titres 
of antibodies induced by chloroplast-derived L1 protein against native or 
denatured insect cell-derived virus-like particles (VLPs). Balb/c mice were 
intraperitoneally immunized with partially purified leaf extracts. Each 
mouse received 30 µg of L1. Animals were boosted at days 21 and 35. 
Freund, mice group immunized with complete Freund’s adjuvant and 
boosted with incomplete Freund’s adjuvant; Alum, mice group 
immunized and boosted with aluminium hydroxide gel; Control, mice 
group immunized with leaf extracts of wild-type plants. Data are 
presented as means and standard errors (n = 5–6). (b) Characterization of 
sera derived from mice immunized with tobacco chloroplast-derived VLPs 
(serum). Denatured (D) and native (N) insect cell-derived VLPs 
(120 ng/blot) were dot-blotted and incubated with H16.V5 or Cam Vir-1 
monoclonal antibody (mAb) or mouse serum as primary antibody. Bovine 
serum albumin was used as a negative control. A representative result 
from three independent experiments is shown.
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protein in the stroma, as well as in the membranous fraction
of the chloroplast, explains the observation that, after extrac-
tion, the foreign protein is present in both the soluble and
insoluble fractions. Unlike L1 protein, when human serum
albumin was expressed in tobacco chloroplasts, inclusion
bodies were observed within the chloroplasts, and the
organelles increased in size to accommodate the aggregates
(Fernández-San Millán et al., 2003). It is probable that human
serum albumin was not properly folded in the chloroplast,
and hence aggregated to finally form inclusion bodies. In
contrast, in the case of L1, with higher expression levels
than those of human serum albumin, it is assumed that L1
monomers assemble into higher order structures that
probably prevent the formation of inclusion bodies.
In this study, it was demonstrated that L1 protein expressed
in tobacco chloroplasts self-assembles into VLPs. The first
step of this process is the formation of the pentameric
capsomer. It has been reported previously that the protection
conferred by the capsomer prevents the full-length L1 protein
from being completely digested by trypsin, yielding a discrete
42-kDa product detected by western blot (Li et al., 1997).
As expected, this 42-kDa product was observed after L1 plant
protein extracts were treated with trypsin, indicating the
correct formation of capsomers. To detect the formation of
higher order structures, plant extracts were subjected to CsCl
density gradient centrifugation. This is a standard method for
the purification of correctly assembled VLPs and has been
used in different protein expression systems, such as insect
cells (Kirnbauer et al., 1993), yeast (Kim et al., 2007), mammalian
cells (Heino et al., 1995) and plants (Biemelt et al., 2003). In
our studies, chloroplast-synthesized L1 protein was present in
CsCl gradient fractions at a density of 1.27–1.31 g/mL, which
indicates the presence of VLPs. Such fractions immunoreacted
with the conformation-specific anti-HPV antibody H16.V5
mAb. The electron microscopy by negative staining of these
fractions confirmed the presence of VLPs, which were also
detected in situ by electron microscopy of leaf chloroplasts.
Sucrose sedimentation analysis of transgenic leaf soluble
proteins revealed that a significant proportion of the L1
antigen assembled into structures of smaller size than insect
cell-derived VLPs. The formation of either small VLPs or only
capsomers has been observed previously in plants (Biemelt
et al., 2003; Kohl et al., 2006; Maclean et al., 2007). Based
on the model proposed by Zhao et al. (2005) on VLP assembly,
smaller particles of 20 or 40 nm, with 12 or 24 capsomers,
respectively, can be formed. Nevertheless, irregular VLPs of
30–50 nm in diameter have been shown to be immunogenic
in humans (Koutsky et al., 2002). The reason for the preferential
assembly of these smaller particles is unknown. Biemelt et al.
(2003) hypothesized that relatively high concentrations of
L1 protein are required for the correct formation of VLPs.
Maclean et al. (2007) targeted the L1 protein to the chloro-
plast and observed that approximately 60% of the VLPs were
55–60 nm. The L1 expression level detected in our plants is
around fivefold higher than that mentioned above. However,
approximately 70% of the observed viral structures were
smaller than 55 nm. Therefore, this result contrasts with the
hypothesis of the importance of a specific L1 protein concen-
tration to achieve a correct self-assembly into VLPs. A possible
explanation for the assembly of smaller VLPs could be the
difference in redox potential during day/night cycles, controlled
by the ferredoxin/thioredoxin system. In our study, the L1
gene was driven by the light-inducible psbA 5′-UTR. We
believe that L1 is preferentially synthesized in the chloroplast
during the light cycle, when the redox potential could be
inadequate for the assembly of VLPs. It must be taken into
account that the formation of disulphide bonds is essential
for the assembly of papillomavirus capsids. Sapp et al. (1998)
demonstrated by specific mutations that two highly conserved
cysteine residues at positions 175 and 428 are involved in the
trimerization of L1 proteins. As the complete capsid consists
of 360 copies of the L1 protein, it is expected from the atomic
model (Modis et al., 2002) that at least 360 disulphide bonds
are formed per VLP. Several reports have confirmed the
formation of disulphide bonds in the chloroplast: human
somatotropin (Staub et al., 2000), cholera toxin B (Daniell
et al., 2001a), immunoglobulin A (IgA) (Mayfield et al., 2003)
and human interferon (Arlen et al., 2007) have been
expressed in their functional forms. However, all of these
proteins have a rather simple structure with less disulphide
bonds (< 10) relative to the full-sized VLP.
Immunization experiments have shown that chloroplast-
derived VLPs are highly immunogenic by the intraperitoneal
route, inducing a specific humoral response. This result is
equivalent to previous reports of the parenteral (Biemelt
et al., 2003; Varsani et al., 2003; Maclean et al., 2007) or oral
(Warzecha et al., 2003) administration of plant-produced L1
antigen. Importantly, neutralizing antibodies were detected
in the sera of mice immunized with plant extracts, confirming
that the L1 protein self-assembles into immunogenic VLPs in
tobacco chloroplasts. However, the neutralization titres were
much lower than the ELISA titres observed in the immuno-
genicity analysis. This could be the result of the difference in
sensitivity between the ELISA and neutralization tests
performed. A similar pattern has been observed previously by
Maclean et al. (2007) using a neutralization assay based on
the production of pseudovirions within mammalian cells
(Pastrana et al., 2004). Neutralizing titres observed in our
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experiments were approximately 10-fold lower than those
reported by Maclean et al. (2007). However, this could be
explained by a lower sensitivity of tests using pseudovirions
produced in acellular systems relative to cellular systems (Fleury
et al., 2007), as only a small proportion of disassembled VLPs
reassemble into pseudovirions in acellular systems.
Interestingly, aluminium hydroxide showed a similar
adjuvant effect to Freund’s adjuvant, which is the most
commonly used adjuvant in animal models. Despite its good
immunostimulatory capacity, the use of Freund’s adjuvant
is not allowed for human vaccination because of its toxicity.
However, aluminium-based compounds have been widely
used as human vaccine adjuvants for more than 70 years.
Currently, they are the most common adjuvants used for
human application (e.g. both commercial vaccines against
HPV include aluminium derivatives). It should be noted that
Maclean et al. (2007) observed that non-adjuvant plant-derived
VLPs elicited higher neutralizing titres than Freund’s adjuvant
VLPs, indicating that the adjuvant could be dispensable or
even deleterious in this case.
In conclusion, the present work provides a new and
economically viable system for HPV vaccine production in
plants. First, L1 proteins from the most carcinogenic types of
HPV can be easily expressed together in the chloroplast because
of the ability of this organelle to process polycistrons. Second,
high expression levels of antigens in chloroplasts will reduce
the amount of plant material required for a single vaccine
dose. Third, the use of aluminium as an adjuvant may facilitate
approval by legal authorities for human clinical trials. It can be
argued that there is no need for a new HPV vaccine when
two vaccines have just arrived on the market. This is true in
developed countries where the high cost of the vaccine is not
an obstacle. However, the high production costs of current
HPV vaccines will hinder their distribution in developing
countries, where they are needed most. In the present world,
the access of developing countries to these vaccines and
other pharmaceuticals will only take place after a general
access in rich countries.
Experimental procedures
Construction of the chloroplast expression vector
For the construction of the pAF chloroplast transformation vector,
the homologous recombination regions trnI–trnA (104 095–106 205
of the GENBANK Accession Z00044) were amplified by PCR from
tobacco DNA with primers 5′-CGATCGGTGCGGGCCTCTTCGCTAT-
TACGCCAGCAGGGGCCTTGTACACAC-3′ and 5′-AAGCTTTGTATCG-
GCTAAGTTCACGAGTTGG-3′, and introduced into a pUC vector by
PvuI-HindIII digestion. The resulting vector was opened with PvuII,
which cuts the intergenic spacer between trnI and trnA. After making
blunt ends, the plastidial tobacco Prrn promoter was introduced. This
sequence (102 539–102 675) was previously cloned by PCR from
tobacco DNA with the following primers: 5′-GCGGCCGCAATGT-
GAGTTTTTGTAGTTGG-3′ and 5′-GCGGCCGCGAATTCGATGCGCT-
TCATATTCGCCC-3′. The resulting vector was digested with EcoRI,
and the aadA sequence was introduced. This sequence was cloned
by PCR from the pFaadAII vector (provided by Dr Christian Eibl,
Ludwig-Maximilians-Universität, Munich, Germany) with the following
primers: 5′-GCGAATTCTAGGGAGGCAACCATGGCTCGTGAAGCGG-3′
and 5′-GGTTACCTGAATTCGTCGACACGCGTGGTACCGATATCT-
TATTTGCCGACTACC-3′. The resulting vector was digested with
SalI-BstEII, and the 3′-terminator region of the psbA gene was
introduced (536–141, GENBANK Accession Z00044). This region was
previously amplified by PCR from tobacco DNA with the following
primers: 5′-GTCGACGAATTCTCTAGAGATCCTGGCCTAGTCTATAGG-
3′ and 5′-GGTTACCTCGAATATAGCTCTTCTTTCTTATTTC-3′.
HPV-16 L1 cDNA (GENBANK Accession AF472508) was provided
by Dr Robert D. Burk (Albert Einstein College of Medicine, New York,
USA). For cloning into the pAF vector, L1 was amplified by PCR
with the primers 5′-CCACATGTCTCTTTGGCTGCCTAGCG-3′ and
5′-GCGGCCGCTCGAGTTACAGCTTACGTTTTTTGC-3′ in order to
introduce the AflIII and NotI sites, and cloned into the pGEM-T vector
(Promega, Madison, WI, USA). L1 was digested with AflIII/NotI and
fused to the promoter and 5′-UTR of the tobacco psbA gene in a
pKS intermediate vector. Finally, the fusion was digested by EcoRV
and NotI and introduced into the pAF vector. The final clone was
sequenced, and its functionality was tested by western blotting of
soluble extracts of E. coli cultures.
Bombardment and regeneration of chloroplast 
transgenic plants
Gold microprojectiles (0.6 µm) coated with pAF-L1 plasmid DNA
were bombarded into tobacco (Nicotiana tabacum var. Petit Havana)
in vitro-grown leaves using the biolistic device PDS1000/He (Bio-Rad,
Hercules, CA, USA), as described previously (Daniell, 1997). After
bombardment, the leaves were cut into small pieces and cultured in
Magenta vessels (Sigma, St. Louis, MO, USA) containing 500 mg/L
spectinomycin dihydrochloride as a selection agent (Molina et al.,
2004). Resistant shoots were subjected to a second round of selection
under the same conditions. Regenerated plants were transplanted
and grown in a phytotron or glasshouse for further experiments.
Southern blot analysis
Total plant DNA was extracted from leaves of 2-month-old plants
using the cetyltrimethylammonium bromide (CTAB) procedure
(Murray and Thompson, 1980). Ten micrograms of total DNA were
digested with HindIII, separated on a 0.8% (w/v) agarose gel and
transferred to a nylon membrane. The chloroplast vector DNA digested
with BglII and BamHI generated a 0.8-kb probe (P1) homologous to
the flanking sequences. A 0.45-kb fragment (P2 probe) of the L1 gene
was amplified by PCR with the following primers: FintL1 (5′-CGACAT-
GGGGAGGAATATGATTTACAGTTTATTTTTC-3′) and RevL1 (5′-
GCGGCCGCTCGAGTTACAGCTTACGTTTTTTGC-3′). Hybridization
was performed using the chemiluminescent AlkPhos direct labelling-
detection system (GE Healthcare, Buckinghamshire, UK). After
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Southern blot confirmation, the plants were transferred to soil.
Seeds from the T0 generation were germinated in vitro on spectino-
mycin selection medium. The T1 seedlings were isolated and cultured
for 4 weeks in Magenta vessels. Finally, the plants were transferred
to pots. Plants from the T0 and T1 generations were analysed for
homoplasmy.
Western blot analysis
Leaf discs (100 mg) were ground in liquid nitrogen, homogenized in
phosphate-buffered saline (PBS; 0.5 M NaCl, pH 7.4) and sonicated
for 10 s. After centrifugation at 20 000 g for 5 min, the supernatant
was considered as the soluble fraction. The pellet was resuspended
in 200 µL of loading buffer (250 mM Tris-HCl, pH 6.8, 4% SDS, 10%
glycerol, 10% β-mercaptoethanol, 0.01% bromophenol blue) and
boiled for 5 min. After centrifugation at 20 000 g for 5 min, the
supernatant was considered as the insoluble fraction. Proteins were
separated on 10% SDS (w/v)-polyacrylamide gels. Proteins were trans-
ferred on to nitrocellulose membranes (Hybond C, GE Healthcare),
blocked overnight in PBS with 0.1% (v/v) Tween-20 (PBS-T) and 5%
skimmed milk (PBS-TM), and incubated for 1 h with Cam Vir-1 primary
antibody (Abcam, Cambridge, UK) diluted 1 : 25 000 in PBS-TM.
After two washes of 10 min in PBS-T, membranes were incubated
for 1 h with a 1 : 25 000 dilution of peroxidase-conjugated rabbit
anti-mouse IgG (Sigma) diluted in PBS-TM. After washing, the
specific signal was detected using the Advanced ECL system (GE
Healthcare), according to the manufacturer’s instructions.
Dot blot analysis
Native and urea-denatured VLPs from insect cell cultures were
applied to a nitrocellulose membrane (Hybond C, GE Healthcare) at
1.5 µL per dot at a concentration of 80 ng/µL. As a negative control,
1.5 µL of 80 ng/µL BSA (Sigma) per dot was used. After drying at
room temperature for 10 min, the membrane was blocked overnight
with 5% PBS-TM. After washing with PBS-T, the dot blot was incubated
for 1 h at room temperature with the following antibodies and sera
diluted in PBS-TM: H16.V5 conformational antibody 1 : 5000 (provided
by Dr Neil Christensen, Penn State College of Medicine, Hershey, PA,
USA), Cam Vir-1 antibody 1 : 20 000, and serum (diluted 1 : 1000)
taken 47 days post-primary immunization from mice immunized with
transgenic plant extracts and aluminium hydroxide. After four
washes with PBS-T, the membranes were incubated for 1 h with a
1 : 20 000 dilution of peroxidase-conjugated rabbit anti-mouse IgG
(Sigma) diluted in PBS-TM. For detection of the chemiluminescent
signal, the procedure was the same as for western blotting.
ELISA quantification of HPV-16 L1 protein
Transformed and untransformed leaves (100 mg) from plants grown
in a glasshouse were ground in liquid nitrogen, resuspended in
500 µL of carbonate buffer (100 mM Na2CO3, pH 10.5), sonicated
for 10 s and centrifuged at 20 000 g for 5 min at 4 °C to remove
cellular debris. The samples were incubated in a 96-well polyvinyl
chloride microtitre plate (Costar Corning, Corning, NY, USA) over-
night at 4 °C. The wells were blocked with PBS-TM (1% skimmed
milk) for 1 h at room temperature, washed three times with PBS-T
and incubated with anti-L1 H16.V5 mAb at 1 : 500 or Cam Vir-1
mAb at 1 : 1500 in PBS-TM (1 h at 37 °C). The wells were washed
three times with PBS-T and incubated with a 1 : 2000 dilution of rab-
bit anti-mouse IgG-peroxidase conjugate in PBS-TM (1 h at 37 °C).
The plates were developed with 2,2′-azino-bis(3-ethylbenzthiazo-
line-6-sulphonic) acid (ABTS) (Roche, Mannheim, Germany). The re-
action was read at 405 nm in a microtitre plate reader (Multiskan Ex,
Labsystems, Helsinki, Finland). The standard curve for calculating the
amount of recombinant protein with H16.V5 mAb was obtained by
plating purified VLPs produced in insect cells by baculovirus infec-
tion, as described below. VLPs were used in the range of 30–150 ng
per well in 100 mM PBS (pH 7.4). For the standard curve with Cam
Vir-1 mAb, insect cell-derived 6 × His-tagged L1 protein was used,
purified by affinity chromatography with TALON® resin (Clontech
Laboratories, Inc., Mountain View, CA, USA), as described by
the manufacturer. The His-tagged L1 was used in the range of
60–125 ng per well in 100 mM carbonate buffer. Transgenic leaf
extracts were diluted (1 : 1000–1 : 8000) to fit within the linear
range of the standards.
Production of HPV-16 L1 VLPs via baculovirus 
expression in insect cells
This protein was obtained using the Bac-to-Bac© Baculovirus
Expression System (Invitrogen Life Technologies, Carlsbad, CA, USA).
Briefly, the L1 gene described above was subcloned into the pFast-
Bac™1 vector, and the resulting DNA was used to transfer
DH10Bac™ E. coli cells for transposition into the recombinant
bacmid. One microgram of this bacmid was used to transfect 1 × 106
Spodoptera frugiperda Sf21 cells using Cellfectin® Reagent (Invitrogen
Life Technologies). The P1 viral stock was obtained after 72 h of
incubation at 27 °C. The baculovirus was amplified following the
manufacturer’s instructions until a titre of 2.5 × 109 plaque-forming
units/mL was reached. For the production of VLPs, Sf21 insect cells
were grown to a density of (1–1.2) × 106 cells/mL on BD BaculoGold™
TNM-FH Insect Medium (BD Biosciences) supplemented with 50 µg/mL
gentamycin, 50 units/mL penicillin and 50 µg/mL streptomycin in
75-cm2 flasks. Cells were then infected at a multiplicity of infection
of 1–5 and, after 72 h of incubation, infected cells were pelleted by
centrifugation at 1000 g for 5 min.
Purification of VLPs
Insect cells
Pellets of infected insect cells were resuspended in 16 mL of PBS
(0.5 M NaCl)/g cells and sonicated for 1 min. Extracts were layered
on to a 40% sucrose cushion and centrifuged in a swinging bucket
rotor (Kontron TST4114, Kontron, Milano, Italy) for 2 h at 140 000
g at 4 °C. The resulting pellets were resuspended in 10 mL of 27%
(w/v) CsCl in PBS (0.5 M NaCl) solution and centrifuged for 20 h at
260 000 g in a swinging bucket rotor at 10 °C. Five hundred micro-
litre fractions were collected and their densities were measured with
a refractometer. The desired fractions were dialysed overnight
against PBS (0.5 M NaCl).
Plant VLPs
For the extraction of plant VLPs, 4 g of mature tobacco leaves were
ground in liquid nitrogen, homogenized with 26 mL of PBS (0.5 M
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NaCl) and sonicated for 5 min. After centrifugation at 20 000 g for
5 min at 4 °C, supernatants were filtered through a 0.2-µm mesh
and layered on to a 40% sucrose cushion. The rest of the protocol
was similar to that described for insect cell VLP extraction.
Electron microscopy and immunogold labelling
For negative staining, 20-µL samples of the positive fractions in the
CsCl gradient were dialysed against PBS (0.5 M NaCl) on floating
filter pads (pore size, 0.2 µm; Millipore, Bedford, MA, USA). The
samples were placed on to carbon-coated copper grids (400 mesh
size) covered with Formvar membrane and stained with 1% uranyl
acetate solution for 1 min. The samples were inspected under a
Zeiss EM 910 transmission electron microscope (Zeiss, Oberkochen,
Germany) operating at 60 and 80 kV.
For ultrastructural observations, leaf samples from glasshouse-
grown plants were fixed in Karnovsky fixative (4% formaldehyde + 5%
glutaraldehyde in 0.025 M cacodylate buffer, pH 6.7), postfixed in
2% OsO4, dehydrated in an acetone series for 3 days and slowly
embedded in Epon resin for 2 days. Epon blocks were polymerized
at 60 °C for 2 days. Thin sections (~80 nm) were collected on 100-mesh
copper grids, counterstained with uranyl acetate and lead citrate,
and observed using a Philips CM10 transmission electron microscope
(Philips, Hillsboro, OR, USA) operating at 100 kV.
For immunogold labelling, leaf samples were fixed in 4% formal-
dehyde in PBS and dehydrated in acetone by the ‘Progressive Lower-
ing of Temperature’ (PLT) method in a Leica AFS automated system
(Leica, Wetzlar, Germany). Then, samples were infiltrated in Lowicryl
K4M resin and polymerized at –30 °C under ultraviolet light. For im-
munolabelling, Lowicryl sections (thickness, ~80 nm) were deposited
on Formvar- and carbon-coated nickel grids. Immunogold labelling
was performed as described previously (Segui-Simarro et al., 2003).
Briefly, sections were hydrated, floated in PBS, blocked with 5%
BSA in PBS and incubated with the anti-L1 Cam Vir-1 mAb diluted
1 : 200 in 1% BSA for 1 h at room temperature. Sections were then
incubated with an anti-mouse IgG antibody conjugated to 10 nm
gold particles, diluted 1 : 25 in 1% BSA for 45 min. Finally, sections
were washed, air dried, counterstained with uranyl acetate and lead
citrate, and observed in a Philips CM10 transmission electron micro-
scope operating at 100 kV. Controls were performed excluding the
anti-L1 antibody from the incubation buffer.
Trypsin digestion of plant-synthesized L1
Soluble extracts from transgenic plants were partially purified by
a 2-h centrifugation step through a 40% sucrose cushion in a swinging
bucket rotor at 140 000 g. His-tagged L1 monomeric protein and
insect cell-derived VLPs purified by CsCl gradients, as described above,
were used as controls. Approximately 1 µg of protein was digested
for 24 h with 0.5 µg of trypsin (Promega) at 37 °C. Controls without
trypsin were also kept at 37 °C for 24 h. After trypsin inactivation by
boiling for 5 min in loading buffer, samples were analysed by western
blotting.
Analysis of L1 assembly by sucrose sedimentation
To identify different assembly forms of L1, soluble extracts from
insect cells [200 mg/2 mL PBS (0.5 M NaCl)] and tobacco leaves
[500 mg/2 mL PBS (0.5 M NaCl)] were prepared as described
previously for western blotting. The samples were loaded on to
linear 10%–65% (w/v) sucrose gradients. After 2 h of centrifugation
at 150 000 g in a swinging bucket rotor, 20 fractions of 500 µL were
collected, their densities were determined by refractometry, and they
were analysed by ELISA with the H16.V5 conformational antibody.
Sedimentation of L1 capsomers was calibrated with catalase from
bovine liver (Sigma) as sedimentation marker (11.3S).
Analysis of the antigenicity of the chloroplast-derived 
L1 protein by ELISA
Microtitre plates (Maxisorp, Nunc, Rochester, NY, USA) were coated
with plant extracts or VLPs purified from Sf21 insect cells. After
overnight incubation at 4 °C and two washes with PBS-T, the wells
were blocked with PBS supplemented with 1% fetal calf serum (FCS)
for 1 h at 37 °C. The wells were then incubated with either H31.D24
or H16.V5 mAb (1 : 500 and 1 : 5000, respectively) in dilution buffer
(PBS 5×, 1% Tween-20, 10% FCS) for 1 h at 37 °C. The plates were
washed four times and probed with peroxidase-conjugated goat
anti-mouse IgG (Sigma-Aldrich; 1 : 5000 dilution) for 1 h at 37 °C.
After four washes, 0.4 mg/mL o-phenylenediamine and H2O2 diluted
in 25 mM sodium citrate and 50 mM Na2HPO4 were added. The
reaction was stopped after 30 min by the addition of 2 M, and the
optical densities were read at 492 nm.
Immunization of animals
Female Balb/c mice were purchased from Harlan Ibérica (Barcelona,
Spain). Groups of 8-week-old mice (n = 6) were immunized by intra-
peritoneal injection (0.2 mL) with partially purified leaf extracts from
L1-transformed plants in complete Freund’s adjuvant (CFA, Sigma)
or aluminium hydroxide gel (Sigma). The leaves were ground in liquid
nitrogen and homogenized in PBS (0.5 M NaCl). The tissue homogenates
were sonicated, centrifuged and filtered (0.45-µm mesh) to remove
cellular debris. Partial purification of the leaf extracts was performed
by 20% ammonium sulphate precipitation. The precipitated proteins
were resuspended in PBS (0.5 M NaCl) and stored at –80 °C until use.
Each mouse received 30 µg of L1 recombinant protein. The amount
of TSP injected varied between 400 and 500 µg. As a negative control,
a group of mice (n = 6) was intraperitoneally immunized with leaf
protein extracts from wild-type plants (400–500 µg TSP/mouse).
Animals were boosted at days 21 and 35 (using incomplete Freund’s
adjuvant instead of CFA). Blood was collected from the retro-orbital
plexus at days 0, 21, 35 and 47. Pooled sera were titrated against
purified L1 native or denatured VLPs produced in insect cells by an
in-house ELISA test. Denaturation of VLPs was performed by boiling
100 ng aliquots for 10 min (Sasagawa et al., 2005). 96-Well microtitre
plates were coated overnight at 4 °C with 50 µL of insect cell-derived
VLPs (100 ng/well) diluted in PBS (pH 7.4). Subsequently, the wells were
blocked for 1 h at room temperature with PBS-TM and then incubated
for 1 h at 37 °C with serial dilutions of pooled sera in PBS-TM. Then,
the plates were incubated for 1 h at 37 °C with a goat anti-mouse IgG
antibody-horseradish peroxidase conjugate. Washes were performed
between each step with PBS-T. The plates were developed by adding
ABTS. The absorbance at 405 nm was measured in a microplate
plate reader. Antibody titres were expressed as the highest serum
dilution to yield twice the absorbance mean of pre-immune sera.
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Detection of anti-HPV-16 neutralizing antibodies
Neutralization assays were performed by inhibition of infection in
COS-7 cells (a human embryonic kidney cell line expressing SV40
T-antigen) with infectious pseudovirions containing a luciferase
expression plasmid having the SV40 replication origin. In these
assays, HPV-16 pseudovirions were pre-incubated with pooled mice
sera, and the inhibition of gene transfer expression was measured in
COS-7 cells.
HPV-16 pseudovirions were generated as described previously
(Touze and Coursaget, 1998) with some modifications. Briefly,
HPV-16 VLPs (100 µg), purified from Sf21 insect cells infected with a
recombinant baculovirus encoding HPV-16 L1 and L2 genes, were
incubated in 50 mM Tris-HCl buffer (pH 7.5) containing 20 mM
dithiothreitol (DTT) and 1 mM ethyleneglycol-bis(β-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) for 30 min at room temperature.
At this stage, expression plasmids encoding luciferase (10 µg) were
added to the disrupted VLPs. The preparation was then diluted with
increasing concentrations of CaCl2, up to a final concentration of
5 mM, in a buffer containing dimethylsulphoxide (DMSO) and ZnCl2
(10 mM). Pseudovirions were then dialysed in PBS overnight and
stored at 4 °C until use.
After 24 h of incubation at 37 °C, COS-7 cells were washed twice
with Dulbecco’s modified Eagle’s medium (DMEM). Sera (dilutions
1 : 25–1 : 600) from mice immunized with leaf extracts from
L1-transformed plants were incubated with diluted HPV-16 pseudo-
virion stocks. The quantity of HPV-16 pseudovirion was adjusted to
give a luciferase activity of approximately 1500 counts per second
(cps). Pseudovirions (100 µL) were added to 100 µL of mice sera
diluted in incomplete DMEM. After 30 min of incubation at 37 °C,
the mixture was added to the cells. After 3 h at 37 °C, the supernatant
was removed and 200 µL of complete DMEM was added to the
cells. The cells were then incubated for 48 h at 37 °C. Luciferase
gene expression was measured by luminescence assay (luciferase
reporter gene assay with constant light signal; Roche Molecular
Biochemical, Meylan, France). The results were expressed as the
percentage of inhibition of luciferase activity: 100% inhibition
corresponded to the luciferase activity obtained with DNA alone and
0% inhibition corresponded to the luciferase activity obtained with
pseudovirions. The cut-off value used in this assay was an inhibition
of gene transfer greater than 80%, a value previously determined
using the sera from 20 infants and 10 non-immunized mice (diluted
1 : 20) that demonstrated less than 80% inhibition of luciferase
expression.
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